A Phase 1/2 Adaptive Dose Study to Evaluate the Safety and Efficacy of SR-02 Pancreatic Endocrine Cell Clusters Implanted in the Omentum of Adults with Type 1 Diabetes
Latest Information Update: 02 Nov 2024
At a glance
- Drugs SR 02 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms SUGR
- Sponsors Seraxis
- 30 Oct 2024 According to Seraxis media release, company has received the FDAs allowance of an Investigational New Drug (IND) application for a Phase I/II clinical study of its novel islet replacement therapy SR-02
- 29 Oct 2024 New trial record